August 1, 2023
National Institute on Drug Abuse (NIDA)
Purpose:
This notice of special interest (NOSI) invites both preclinical and clinical applications to evaluate the role of social functioning in the treatment of substance use disorders (SUDs) and as potential endpoints for therapeutics development.
Background:
SUDs often correspond with social dysfunction. Namely, DSM V diagnostic criteria for SUD include 1) reduced involvement in social activities because of substance use, 2) failure to meet occupational and societal obligations due to substance use, and 3) continued substance use in the face of recurrent interpersonal problems. These diagnostic criteria illustrate that social dysfunction is not only a common consequence of SUD, but also a clinically recognized feature of its pathology. Therefore, interventions that improve social function would be expected to reduce SUD diagnostic scores related to social dysfunction and could also promote a decrease in drug use. However, the relationships between social function, SUD severity, and drug use have not been explicitly determined. This Notice of Special Interest invites both preclinical and clinical applications to evaluate the role of social functioning in the treatment of SUDs as well as the development of social function endpoints for therapeutics development.
Areas of Interest include (but are not limited to):
Application and Submission Information
This notice applies to due dates on or after October 5, 2023 and subsequent receipt dates through September 8, 2026.
Submit applications for this initiative using one of the following notice of funding opportunity (NOFO) or any reissues of these announcements through the expiration date of this notice.
All instructions in the SF424 (R&R) Application Guide and the NOFO used for submission must be followed.
Applications nonresponsive to terms of this NOSI will not be considered for the NOSI initiative.
Please direct all inquiries to the Scientific/Research, Peer Review, and Financial/Grants Management contacts in Section VII of the listed notice of funding opportunity.
Scientific/Research Contact(s)
Drew Townsend, PhD
Division of Therapeutics and Medical Consequences
National Institute on Drug Abuse (NIDA)
Email: [email protected]
Telephone: 301-443-4577
Peer Review Contact(s)
Examine your eRA Commons account for review assignment and contact information (information appears two weeks after the submission due date).
Financial/Grants Management Contact(s)
Please direct all inquiries to the Financial/Grants Management contacts in Section VII of the listed notice of funding opportunity.